Rheumatoid Arthritis

---

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation, pain, swelling, and progressive destruction of cartilage and bone. While RA primarily affects the joints, it is increasingly recognized as a systemic condition driven by widespread immune dysregulation. In individuals with RA, immune tolerance fails, leading to sustained activation of inflammatory pathways that damage both local joint tissue and distant organs.

Growing evidence suggests that the gut plays an important upstream role in rheumatoid arthritis. The gastrointestinal tract is a major immune organ, constantly educating immune cells to distinguish between harmless signals and true threats. In RA, this immune education process appears to be disrupted. Patients with RA frequently exhibit alterations in gut microbiota composition, reduced microbial diversity, and impaired production of beneficial microbial metabolites, particularly short-chain fatty acids such as butyrate.

Butyrate plays a central role in maintaining immune balance. One of its most important functions in the context of RA is the regulation of immune cell behavior. RA is associated with an imbalance between pro-inflammatory T helper cells (including Th1 and Th17 cells) and regulatory T cells (Tregs), which normally suppress excessive immune responses. Butyrate promotes the differentiation and expansion of Tregs, helping restore immune tolerance and reduce autoimmune-driven inflammation [1, 2].

At the molecular level, butyrate suppresses inflammatory signaling pathways that are central to RA pathogenesis. It inhibits activation of nuclear factor kappa B (NF-κB), a key transcription factor that drives the expression of pro-inflammatory cytokines such as tumor necrosis factor–α (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17). These cytokines are major contributors to synovial inflammation, cartilage degradation, and bone erosion in rheumatoid arthritis. By reducing their expression, butyrate helps dampen the inflammatory cascade that fuels joint damage [3]. Anti-inflammatory butyrate-producing bacteria, such as Faecalibacterium prausnitzii, were shown to provide a beneficial effect in the RA mouse model by attenuating IL-17 levels [4]. 

Butyrate also exerts epigenetic control over immune responses. As a natural histone deacetylase (HDAC) inhibitor, butyrate alters gene expression patterns in immune cells, shifting them away from a pro-inflammatory phenotype and toward a more regulated, tolerant state. This epigenetic regulation allows butyrate to promote longer-lasting immune stability rather than short-term suppression of symptoms, a feature that is especially relevant in chronic autoimmune diseases such as RA [5].

In addition to its direct effects on immune cells, butyrate indirectly influences RA by supporting gut barrier integrity. Increased intestinal permeability, often referred to as “leaky gut,” has been observed in RA and allows bacterial components to enter the bloodstream, triggering systemic inflammation and worsening autoimmune activity. By strengthening tight junctions, supporting mucus production, and fueling intestinal epithelial cells, butyrate helps reduce the translocation of inflammatory microbial products and lowers systemic immune activation.

Animal studies provide further support for butyrate’s role in RA. In experimental models of inflammatory arthritis, oral supplementation with sodium butyrate reduces joint swelling, inflammatory cell infiltration, and cartilage destruction while increasing regulatory immune responses. These findings suggest that restoring butyrate signaling can mitigate both local joint inflammation and systemic immune dysregulation [6].

Unfortunately, factors common in modern life—including low dietary fiber intake, antibiotic exposure, chronic stress, and aging—are associated with reduced populations of butyrate-producing bacteria and lower intestinal butyrate levels. This decline may weaken natural immune-regulatory mechanisms and increase susceptibility to autoimmune diseases such as rheumatoid arthritis. Supporting butyrate levels, either by enhancing endogenous production or through targeted supplementation, represents a strategy aimed at addressing upstream immune imbalance rather than solely managing downstream inflammation.

BACK

References

1. Furusawa,      Y., Obata, Y., Fukuda, S. et al. Commensal      microbe-derived butyrate induces the differentiation of colonic regulatory      T cells. Nature 504, 446–450      (2013). https://doi.org/10.1038/nature12721

2. Pang      A, Pu S, Pan Y, Huang N, Li D. Short-chain fatty acids from gut microbiota      restore Th17/Treg balance in rheumatoid arthritis: Mechanisms and      therapeutic potential. J Transl Autoimmun. 2025;11:100316. Published 2025 Sep 16.      doi:10.1016/j.jtauto.2025.100316

3. Chang      PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate      regulates intestinal macrophage function via histone deacetylase      inhibition. Proc Natl Acad Sci U S A. 2014;111(6):2247-2252. doi:10.1073/pnas.1322269111

4. Moon,      J., Lee, A. R., Kim, H., Jhun, J., Lee, S. Y., Choi, J. W., Jeong, Y.,      Park, M. S., Ji, G. E., Cho, M. L., & Park, S. H. (2023).      Faecalibacterium prausnitzii alleviates inflammatory arthritis and      regulates IL-17 production, short chain fatty acids, and the intestinal      microbial flora in experimental mouse model for rheumatoid arthritis. Arthritis research & therapy, 25(1), 130.      https://doi.org/10.1186/s13075-023-03118-3

5. Koh      A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to      Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell.      2016;165(6):1332-1345. doi:10.1016/j.cell.2016.05.041

6. Hui W, Yu D, Cao Z, Zhao X. Butyrate inhibit collagen-induced arthritis via Treg/IL-10/Th17 axis. Int Immunopharmacol. 2019;68:226-233. doi:10.1016/j.intimp.2019.01.018